NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Enhanced Genomics

Enhanced Genomics

Private
CambridgeHealthcare & Life Scienceshttps://enhancedgenomics.com/

Last Round

Series A

Oct 20, 2022

Est. Valuation

$31.18M

Total Funding Raised

$21.41M

Company Overview

Enhanced Genomics is a biotechnology company that develops a 3D multi-omics platform to map genome folding and identify therapeutic targets for drug discovery.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Healthcare Analytics, Medical AI

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Application

Keywords

drug discovery3D genomicsmulti-omicstarget discoverynon-coding genomechromatin conformationgenome foldingprecision medicinebiotech platformin silico drug discoveryGWASgenome-wide association studyAI drug discoverytherapeutic target validationbioinformatics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Enhanced Genomics Comparables

Compare Enhanced Genomics with similar companies based on industry and business-model similarity.

Enhanced Genomics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Nucleome Therapeutics
87%
Genomics
77%
Arima Genomics
77%

Enhanced Genomics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AOct 20, 2022
SeedMar 26, 2021

Key People

Founding team and executive leadership

Dan Turner

Chief Technology Officer

Executive Team

Julie Bailey

Consulting CFO

Executive Team

Enhanced Genomics Investors

Notable investors and investment history

Enhanced Genomics investors
InvestorRounds
Start CodonSeed
BGFSeries A
Meltwind AdvisorySeries A
Bioqube VenturesSeries A, Seed
Parkwalk AdvisorsSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Oct 30, 2024

    Monthly visitors increased 280% MoM to 3.2K.

Enhanced Genomics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Enhanced Genomics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Enhanced Genomics's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge
Employee Range16
Year Founded2020
Last FundingOct 20, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.